Inflammatory facial acne. Acne vulgaris
Conditions
Interventions
Intervention 1: Intervention group: Group 1: Treatment with oral isotretinoin 20 mg every other day. Intervention 2: Intervention group: Group 2: Treatment with a combination of oral isotretinoin 20 m
Sponsors
Iran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
15 Years to 50 Years
Inclusion criteria
Inclusion criteria: Patients with a confirmed diagnosis of inflammatory facial scarring acne The patient has not received any treatment for her illness within the past three months Patient cooperation in carrying out therapeutic interventions and attending all treatment sessions Lack of serious underlying disease
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The rate of prevention of inflammatory facial acne scars. Timepoint: Assessments are performed 2, 4, and 6 weeks after the start of treatment and 1 month after the end of treatment. Method of measurement: 1. Taking pictures with a Visioface camera to assess the severity of acne scars in terms of width, depth and area. 2. Determining the severity of acne using the Leeds revised acne grading system, which is based on the lesions in the photo and comparing them with the existing criteria, the severity of acne is scored from 1 to 12. 3. Assessing the severity of acne using the global acne grading system, which is based on the location of acne lesions on the face and also based on the type of lesions from comedones to papules, pustules and nodulocystic acne, with a score from 1 to 44, with grades 1 to 18 being mild, 19 to 30 being moderate, 31 to 38 being severe and grades equal to or greater than 39 being very severe. 4. The degree of satisfaction of the doctor and patient with the treatment based on the phsician/patient global assessment score: (completely satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied and completely dissatisfied). | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment safety, treatment tolerability. Timepoint: Assessments are performed 2, 4, and 6 weeks after the start of treatment and 1 month after the end of treatment. Method of measurement: Evaluation of treatment-related complications including erythema, hyperpigmentation, scaling, and pain using a VesioFace camera. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamidreza Fallahinejad
Iran University of Medical Sciences
Outcome results
None listed